NASDAQ:MYGN Myriad Genetics (MYGN) Stock Price, News & Analysis → The Next Nvidia? (From InvestorPlace) (Ad) Free MYGN Stock Alerts $19.47 +0.25 (+1.30%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$19.40▼$20.0950-Day Range$17.98▼$23.5052-Week Range$13.82▼$24.21Volume820,170 shsAverage Volume623,251 shsMarket Capitalization$1.76 billionP/E RatioN/ADividend YieldN/APrice Target$23.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Myriad Genetics alerts: Email Address Myriad Genetics MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside19.0% Upside$23.17 Price TargetShort InterestBearish6.08% of Shares Sold ShortDividend StrengthN/ASustainability-0.60Upright™ Environmental ScoreNews Sentiment0.07Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.36) to ($0.09) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.01 out of 5 starsMedical Sector356th out of 904 stocksDiagnostic Substances Industry6th out of 13 stocks 2.2 Analyst's Opinion Consensus RatingMyriad Genetics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 3 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageMyriad Genetics has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.08% of the outstanding shares of Myriad Genetics have been sold short.Short Interest Ratio / Days to CoverMyriad Genetics has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Myriad Genetics has recently decreased by 3.00%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMyriad Genetics does not currently pay a dividend.Dividend GrowthMyriad Genetics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMyriad Genetics has received a 58.24% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Genomics analysis tools", "Computerized clinical decision support software", and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Myriad Genetics is -0.60. Previous Next 2.3 News and Social Media Coverage News SentimentMyriad Genetics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Myriad Genetics this week, compared to 3 articles on an average week.Search Interest3 people have searched for MYGN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Myriad Genetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Myriad Genetics is held by insiders.Percentage Held by Institutions99.02% of the stock of Myriad Genetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Myriad Genetics are expected to grow in the coming year, from ($0.36) to ($0.09) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Myriad Genetics is -6.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Myriad Genetics is -6.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMyriad Genetics has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Myriad Genetics Stock (NASDAQ:MYGN)Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.Read More MYGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MYGN Stock News HeadlinesMay 5, 2024 | americanbankingnews.comMyriad Genetics (MYGN) to Release Earnings on TuesdayMay 2, 2024 | finance.yahoo.comYourBio Health Congratulates Myriad Genetics on One Million Sales of SneakPeek® Tests Enabled by YourBio's Virtually Painless TAP TechnologyMay 5, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 30, 2024 | finance.yahoo.comMyriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024April 28, 2024 | msn.comAroa Biosurgery to target US$300 million trauma market with Myriad productsApril 17, 2024 | tmcnet.comNearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health MonitorApril 17, 2024 | finance.yahoo.comNearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health MonitorApril 17, 2024 | finance.yahoo.comNearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health MonitorMay 5, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 17, 2024 | globenewswire.comNearly Half of Americans Say They've Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health MonitorApril 16, 2024 | globenewswire.comNew Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal ScreenApril 15, 2024 | barrons.comMyriad Genetics Inc.April 11, 2024 | uk.investing.comMyriad Genetics psychotropic test 'GeneSight' linked to lower hospitalization in depression patientsApril 9, 2024 | globenewswire.comMyriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight TestingApril 6, 2024 | finance.yahoo.comNovavax (NVAX) Down 3.2% Since Last Earnings Report: Can It Rebound?March 21, 2024 | globenewswire.comMyriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority DateMarch 21, 2024 | finanznachrichten.deMyriad Genetics, Inc.: Myriad Genetics Announces Patent Granted for SneakPeek Snap DeviceMarch 20, 2024 | globenewswire.comMyriad Genetics Announces Patent Granted for SneakPeek® Snap DeviceMarch 16, 2024 | finance.yahoo.comMYGN Apr 2024 30.000 callMarch 16, 2024 | finance.yahoo.comMYGN Aug 2024 21.000 callMarch 16, 2024 | finance.yahoo.comMYGN May 2024 18.000 callMarch 14, 2024 | msn.comCiti starts Catalyst at buy, cites rare disease drug portfolioMarch 1, 2024 | markets.businessinsider.comMyriad Genetics: Hold Rating Amidst Growth and Market UncertaintyFebruary 29, 2024 | finance.yahoo.comMyriad Genetics Full Year 2023 Earnings: EPS Misses ExpectationsFebruary 28, 2024 | finance.yahoo.comMyriad Genetics, Inc. (NASDAQ:MYGN) Q4 2023 Earnings Call TranscriptFebruary 28, 2024 | finance.yahoo.comQ4 2023 Myriad Genetics Inc Earnings CallFebruary 28, 2024 | markets.businessinsider.comMyriad Genetics: Hold Rating Maintained Amid Balanced Performance and Cautious OutlookSee More Headlines Receive MYGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/05/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryBiotechnology Current SymbolNASDAQ:MYGN CUSIP62855J10 CIK899923 Webwww.myriad.com Phone(801) 584-3600Fax801-584-3640Employees2,700Year Founded1991Price Target and Rating Average Stock Price Target$23.17 High Stock Price Target$31.00 Low Stock Price Target$14.00 Potential Upside/Downside+19.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-263,300,000.00 Net Margins-34.96% Pretax Margin-34.81% Return on Equity-8.03% Return on Assets-5.24% Debt Debt-to-Equity Ratio0.05 Current Ratio2.01 Quick Ratio1.87 Sales & Book Value Annual Sales$753.20 million Price / Sales2.34 Cash FlowN/A Price / Cash FlowN/A Book Value$9.53 per share Price / Book2.04Miscellaneous Outstanding Shares90,480,000Free Float88,668,000Market Cap$1.76 billion OptionableOptionable Beta1.96 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Paul J. Diaz (Age 62)CEO, President & Director Comp: $2.31MMr. Samraat S. Raha (Age 51)Chief Operating Officer Comp: $514.76kDr. Dale Muzzey Ph.D. (Age 44)Chief Scientific Officer Comp: $816.5kMr. Mark S. Verratti (Age 56)Chief Commercial Officer Comp: $915.81kMr. Scott J. Leffler (Age 49)Chief Financial Officer Ms. Natalie Munk (Age 43)Principal Accounting Officer Dr. Kevin Richard Haas Ph.D. (Age 38)Chief Technology Officer Comp: $580.36kMr. Matthew ScaloSenior Vice President of Investor RelationsMr. Glenn FarrellSenior VP & Chief Marketing OfficerMs. Shereen Solaiman (Age 51)Chief People Officer More ExecutivesKey CompetitorsMeridian BioscienceNASDAQ:VIVOCelldex TherapeuticsNASDAQ:CLDXIntellia TherapeuticsNASDAQ:NTLAHeskaNASDAQ:HSKANeogenNASDAQ:NEOGView All CompetitorsInsiders & InstitutionsNordea Investment Management ABBought 6,807 shares on 5/2/2024Ownership: 0.142%Mirae Asset Global Investments Co. Ltd.Bought 149,234 shares on 5/1/2024Ownership: 0.370%Allspring Global Investments Holdings LLCBought 4,193 shares on 4/30/2024Ownership: 0.010%Principal Financial Group Inc.Sold 2,406 shares on 4/29/2024Ownership: 0.519%China Universal Asset Management Co. Ltd.Bought 6,987 shares on 4/29/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions MYGN Stock Analysis - Frequently Asked Questions Should I buy or sell Myriad Genetics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares. View MYGN analyst ratings or view top-rated stocks. What is Myriad Genetics' stock price target for 2024? 6 brokerages have issued twelve-month target prices for Myriad Genetics' shares. Their MYGN share price targets range from $14.00 to $31.00. On average, they predict the company's share price to reach $23.17 in the next year. This suggests a possible upside of 19.0% from the stock's current price. View analysts price targets for MYGN or view top-rated stocks among Wall Street analysts. How have MYGN shares performed in 2024? Myriad Genetics' stock was trading at $19.14 at the beginning of 2024. Since then, MYGN shares have increased by 1.7% and is now trading at $19.47. View the best growth stocks for 2024 here. When is Myriad Genetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our MYGN earnings forecast. How can I listen to Myriad Genetics' earnings call? Myriad Genetics will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Myriad Genetics' earnings last quarter? Myriad Genetics, Inc. (NASDAQ:MYGN) posted its quarterly earnings data on Tuesday, February, 27th. The company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.03. The business had revenue of $196.60 million for the quarter, compared to the consensus estimate of $194.80 million. Myriad Genetics had a negative net margin of 34.96% and a negative trailing twelve-month return on equity of 8.03%. The company's quarterly revenue was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.20) earnings per share. What ETFs hold Myriad Genetics' stock? ETFs with the largest weight of Myriad Genetics (NASDAQ:MYGN) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Invesco Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).SPDR S&P 600 Small Cap ETF (SLY). What guidance has Myriad Genetics issued on next quarter's earnings? Myriad Genetics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of 0.000-0.050 for the period, compared to the consensus EPS estimate of -0.010. The company issued revenue guidance of $820.0 million-$840.0 million, compared to the consensus revenue estimate of $819.3 million. What is Paul Diaz's approval rating as Myriad Genetics' CEO? 12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees. What other stocks do shareholders of Myriad Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS). Who are Myriad Genetics' major shareholders? Myriad Genetics' stock is owned by many different institutional and retail investors. Top institutional investors include Principal Financial Group Inc. (0.52%), Mirae Asset Global Investments Co. Ltd. (0.37%), Assenagon Asset Management S.A. (0.22%), Nordea Investment Management AB (0.14%), Fifth Third Bancorp (0.09%) and State of Alaska Department of Revenue (0.06%). Insiders that own company stock include Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Jerry S Lanchbury, Nicole Lambert, Richard Bryan Riggsbee and S Louise Phanstiel. View institutional ownership trends. How do I buy shares of Myriad Genetics? Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Myriad Genetics have any subsidiaries? The following companies are subsidiares of Myriad Genetics: Assurex Health Inc., Assurex Health Ltd, Counsyl, Crescendo Bioscience, Crescendo Bioscience LLC, Javelin Pharmaceuticals, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GK, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad Services GmbH, Myriad Women’s Health, Myriad Women’s Health Inc, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Rules-Based Medicine, and Sividon Diagnostics.Read More This page (NASDAQ:MYGN) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThe only AI company you should be looking atBehind the MarketsMysterious Gold Leverage Just AnnouncedStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Myriad Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.